Current Topics

Trimodality Therapy May Improve Outcomes of Patients with Pleural Mesothelioma (7/14/2009)
Researchers involved in a multi-center U.S. trial have reported neoadjuvant chemotherapy with Alimta® (pemetrexed) and Platinol® (cisplatin), followed by pneumonectomy and radiation therapy, may improve survival of patients with Stage I-III pleural malignant mesothelioma. The details of this study appeared in the June 20, 2009 issue of the Journal of Clinical Oncology.

Alimta® with or Without a Platinum Compound Confirmed Effective Palliation for Peritoneal Mesothelioma (4/9/2009)
Researchers from Italy have reported that Alimta® (pemetrexed), with or without a platinum compound, is active and well tolerated in patients with peritoneal mesothelioma. The details of this study appeared in the May 1, 2009 issue of Lung Cancer.

Alimta® plus Paraplatin Effective Palliation for Pleural Mesothelioma (4/8/2009)
Researchers from the United Kingdom have reported that Alimta® (pemetrexed) and Paraplatin® (carboplatin) may be effective palliation for patients with malignant pleural mesothelioma. The details of this study appeared in the May 1, 2009 issue of Lung Cancer.

Alimta® and Gemzar® Effective for Peritoneal Mesothelioma (7/22/2008)
Researchers affiliated with a multicenter U.S. trial have reported that the combination of Alimta® (pemetrexed) and Gemzar® (gemcitabine) was active in patients with peritoneal mesothelioma. The details of this study appeared in the July 20, 2008 issue of the Journal of Clinical Oncology.

Navelbine® and Platinol® Effective for Mesothelioma (7/10/2008)
Researchers from Denmark have reported that the combination of Navelbine® (vinorelbine) and Platinol® (cisplatin) is highly active in patients with newly diagnosed non-resectable malignant pleural mesothelioma. The details of this study appeared in an early online publication in the British Journal of Cancer on June 10, 2008.